Role of the RAS Pathway Activation on the Biology and Drug Response of Acute Myeloid Leukemias

RAS 通路激活对急性髓系白血病生物学和药物反应的作用

• 批准号: 468616
• 负责人: Barab Frdric
• 金额: $ 64.93万
• 依托单位: Universit Laval
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-09-01 至 2027-09-01
• 项目状态: 未结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=468616&lang=en
• 关键词: Clonal Evolution; Crispr Induced Gene Mutation; Engineered Human Leukemia Models; Gene Expression Profiles; Human Acute Leukemias; Kmt2a Fusion Gene; Leukemic Stem Cell Frequency; Ras Pathway; Small Molecule High-Throughput Screen; Xenograft Models

Despite advances in the treatment of acute leukemias over the past 20 years, they are still a leading cause of death by cancer before the age of 40. Also, their incidence grows exponentially after 60 years old and the overall survival 2 years after diagno

尽管在过去的20年里，急性白血病的治疗取得了进展，但它们仍然是40岁之前癌症死亡的主要原因。此外，60岁以后，其发病率呈指数增长，诊断后2年的总生存率